EUVIMEDEUVIMED entdecken
Crossref

Investigation of the Potency of KALA and REV Cell‐Penetrating Peptides for In Vitro/In Vivo Delivery of an HPV Multiepitope DNA Construct

Haleh Feyzyab, Alireza Milani, Elnaz Agi, Mehrdad Hashemi, Azam Bolhassani iD

Journal of Peptide Science · 2025

DOI: 10.1002/psc.70000 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Peptide Science, 2025. Verfasst von Haleh Feyzyab und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Hauptthemen laut MEDLINE: Cell-Penetrating Peptides, Vaccines, DNA, Epitopes, Papillomavirus Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Developing human papillomavirus (HPV) therapeutic DNA vaccines requires an effective delivery system, such as cell‐penetrating peptides (CPPs). In the current study, the multiepitope DNA constructs harboring the immunogenic and conserved epitopes of the L1, L2, and E7 proteins of HPV16/18 (pcDNA‐L1‐L2‐E7 and pEGFP‐L1‐L2‐E7) were delivered using KALA and REV CPPs with different properties in vitro and in vivo. Herein, after confirmation of the REV/DNA and KALA/DNA complexes, their stability was investigated against DNase I and serum protease. Then, their entry into HEK‐293T eukaryotic cells was analyzed by qualitative and quantitative methods. Finally, anti‐tumor effects of the peptide/DNA complexes were investigated in the C57BL/6 mouse model. Based on the obtained data, the REV/DNA and KALA/DNA complexes at the N/P ratio of 5:1 demonstrated successful penetration into HEK‐293T cells. Furthermore, in vivo studies represented that the REV/DNA (survival rate: 75%) and KALA/DNA (survival rate: 50%) complexes provided significant protection against C3 tumors in mice. Indeed, REV CPP exhibited a higher survival rate and lower tumor volume than KALA CPP, 50 days after the C3 challenge. These findings represented the potential of KALA and REV CPPs, especially REV, as promising gene delivery systems for developing HPV therapeutic DNA vaccine candidates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell-Penetrating PeptidesVaccines, DNAEpitopesPapillomavirus VaccinesHumansAnimalsHEK293 CellsMiceMice, Inbred C57BLFemaleHuman papillomavirus 16

Stichwörter der Autor:innen

KALAREVantitumor effectcancercell‐penetrating peptidehuman papillomavirus

Substanzen

Cell-Penetrating PeptidesVaccines, DNAEpitopesPapillomavirus Vaccines

Autor:innen und Institutionen

  • Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
  • Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
  • Blood Diseases Research Center (BDRC), Iranian Comprehensive Hemophilia Care Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.

ORCID-Profile: Azam Bolhassani

Zitieren

APA

Feyzyab, H., Milani, A., Agi, E., Hashemi, M., & Bolhassani, A. (2025). Investigation of the Potency of KALA and REV Cell‐Penetrating Peptides for In Vitro/In Vivo Delivery of an HPV Multiepitope DNA Construct. Journal of Peptide Science. https://doi.org/10.1002/psc.70000

Vancouver

Feyzyab H, Milani A, Agi E, Hashemi M, Bolhassani A. Investigation of the Potency of KALA and REV Cell‐Penetrating Peptides for In Vitro/In Vivo Delivery of an HPV Multiepitope DNA Construct. Journal of Peptide Science. 2025. doi:10.1002/psc.70000

BibTeX
@article{Feyzyab2025,
  author = {Feyzyab, Haleh and Milani, Alireza and Agi, Elnaz and Hashemi, Mehrdad and Bolhassani, Azam},
  title = {Investigation of the Potency of KALA and REV Cell‐Penetrating Peptides for In Vitro/In Vivo Delivery of an HPV Multiepitope DNA Construct},
  journal = {Journal of Peptide Science},
  year = {2025},
  doi = {10.1002/psc.70000}
}
Kostenlos starten →